Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indices hover at elevated levels
Mon, 18 Nov 01:30 pm

Backed by strong buying sentiment, Indian share markets continued to trade at stratospheric levels in the post-noon trading session. All the sectoral indices are trading in the green with capital goods, banking and FMCG stocks being the biggest gainers.

BSE-Sensex is up 350 points and NSE-Nifty is trading 99 points up. BSE Mid Cap is trading up 1.1% and BSE Small Cap index is trading up 0.8%. The rupee is trading at 62.6 to the US dollar.

Mining stocks are trading mixed with Manganese Ore Industries Ltd (MOIL) and Hindustan Zinc being the biggest gainers whereas Sesa Sterlite and Ashapura Minechem are among the major losers. As per a leading financial daily, Coal India Ltd (CIL) has raised the charges for transporting coal from minefields to loading points in light of the rising diesel prices. CIL had last effected a significant hike in transport charges in 2009. In addition to higher fuel prices, there has also been an increase in salaries and wages of employees and contract employees engaged in coal transportation. According to the revised price schedule, the transportation cost for 3-10 km has been raised by Rs 13 to Rs 57 per tonne resulting in a 29.5% increase. For distances of 10-20 km, the surface transport charges have been increased by 51% to Rs 116 per tonne. This price-hike is expected to raise the fuel cost for power producers. CIL stock is currently trading down by 0.3%.

Indian pharma stocks are trading in green with Elder pharma and Torrent pharma being the leading gainers. As per the financial daily, Ranbaxy laboratories, is planning to supply medicines in Japan from its Indian facilities. The company is looking forward to get approvals from regulatory agency in Japan. Reportedly, the step is in line with hybrid model between Ranbaxy and its parent company Dacihii Sankyo. Daiichi Sankyo Espha will be the vehicle to introduce generic products in Japan, through a joint team set up for development, sales and distribution. This will be a positive development for the company, if it gets clearance from Japan drug regulators. The presence of Daiichi Sankyo in Japan, will help in better the sales in this geography. Ranbaxy is currently trading up by 2.5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indices hover at elevated levels". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.